Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) Director Sells 124,690 Shares of Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Director Peter Neupert sold 124,690 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $25.15, for a total value of $3,135,953.50. Following the transaction, the director owned 130,625 shares of the company’s stock, valued at approximately $3,285,218.75. The trade was a 48.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Adaptive Biotechnologies Stock Up 3.8%

NASDAQ ADPT traded up $0.93 during trading on Wednesday, hitting $25.49. The stock had a trading volume of 2,145,752 shares, compared to its average volume of 2,579,911. The company has a debt-to-equity ratio of 2.22, a quick ratio of 4.68 and a current ratio of 4.79. Adaptive Biotechnologies Corporation has a 12 month low of $12.00 and a 12 month high of $26.16. The company’s 50-day moving average price is $21.75 and its two-hundred day moving average price is $17.24. The company has a market capitalization of $4.07 billion, a PE ratio of -62.17 and a beta of 2.08.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.12). The business had revenue of $71.55 million during the quarter, compared to analyst estimates of $65.44 million. Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. The firm’s quarterly revenue was up 21.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.17) earnings per share. As a group, sell-side analysts forecast that Adaptive Biotechnologies Corporation will post -0.4 EPS for the current year.

Institutional Investors Weigh In On Adaptive Biotechnologies

A number of hedge funds have recently made changes to their positions in the business. 1492 Capital Management LLC purchased a new position in shares of Adaptive Biotechnologies in the fourth quarter worth about $1,484,000. Jupiter Asset Management Ltd. lifted its stake in shares of Adaptive Biotechnologies by 33.8% during the 4th quarter. Jupiter Asset Management Ltd. now owns 362,811 shares of the company’s stock valued at $5,892,000 after buying an additional 91,683 shares in the last quarter. Westfield Capital Management Co. LP bought a new position in Adaptive Biotechnologies in the 4th quarter worth approximately $65,942,000. Rhenman & Partners Asset Management AB grew its stake in Adaptive Biotechnologies by 22.2% in the 4th quarter. Rhenman & Partners Asset Management AB now owns 605,000 shares of the company’s stock valued at $9,825,000 after buying an additional 110,000 shares in the last quarter. Finally, Jennison Associates LLC grew its stake in Adaptive Biotechnologies by 103.9% in the 4th quarter. Jennison Associates LLC now owns 2,674,668 shares of the company’s stock valued at $43,437,000 after buying an additional 1,363,181 shares in the last quarter. 99.17% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Morgan Stanley boosted their price target on Adaptive Biotechnologies from $20.00 to $22.00 and gave the stock an “equal weight” rating in a report on Thursday, July 30th. Guggenheim upped their price target on shares of Adaptive Biotechnologies from $22.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Friday, July 17th. Piper Sandler increased their price objective on Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a report on Tuesday, August 4th. Finally, JPMorgan Chase & Co. lowered their target price on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.42.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.